Aaron Cowen’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$157M Buy
4,515,531
+114,448
+3% +$3.38M 2.87% 6
2026
Q1
$102M Buy
4,401,083
+295,048
+7% +$6.66M 2.59% 12
2025
Q4
$82.6M Buy
4,106,035
+402,583
+11% +$8.38M 1.69% 22
2025
Q3
$68.3M Buy
3,703,452
+290,664
+9% +$5.71M 1.75% 18
2025
Q2
$74.3M Buy
3,412,788
+1,075,292
+46% +$22.3M 2.24% 14
2025
Q1
$43.2M Buy
2,337,496
+91,496
+4% +$2.24M 1.6% 18
2024
Q4
$59.8M Buy
2,246,000
+400,838
+22% +$11.5M 2.04% 15
2024
Q3
$43.4M Buy
1,845,162
+132,459
+8% +$3.01M 1.39% 26
2024
Q2
$31.8M Buy
1,712,703
+148,994
+10% +$2.66M 1.17% 31
2024
Q1
$27.9M Buy
+1,563,709
New +$31.5M 1.04% 33

Other funds holding AVBP

Aaron Cowen's AVBP Position: Q2 2026 in Review

Aaron Cowen increased its ArriVent BioPharma (AVBP) stake by 2.6% in Q2 2026, buying an estimated $3.38M and bringing the position to 4,515,531 shares worth $157M. The position accounts for 2.87% of the portfolio, ranked #6.

Aaron Cowen first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 156 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Aaron Cowen held 4,515,531 shares of ArriVent BioPharma worth $157M as of Q2 2026.
  • Aaron Cowen bought 114,448 ArriVent BioPharma shares in Q2 2026, an estimated $3.38M.
  • ArriVent BioPharma made up 2.87% of Aaron Cowen's portfolio in Q2 2026, its #6 holding.
  • Aaron Cowen first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 156 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.